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Abstract    
Background: Studies suggest an association between panic disorder (PD) and impairment of lung function. Objectives: 
To evaluate lung function in 11 asymptomatic PD patients and to investigate antipanic drug effects on respiratory function. 
Method: Lung function was evaluated on two different occasions (with antipanic drugs and after drug washout). It was 
comprised of a spirometric evaluation and a bronchodilation test (salbutamol inhalation). Subjective Units of Disturbance 
Scale (SUDS) was applied before and after each spirometric assessment. Results: One patient showed mild obstructive 
airway impairment. Before bronchodilation test forced expiratory volume in 1 sec (FEV1) and forced expiratory flow betwe-
en 25% and 75% of the forced vital capacity (FEF25-75) were significantly higher in patients on antipanic drugs than in those 
in the washout period. After salbutamol inhalation, only FEV1 was significantly higher in patients with antipanic drugs in 
comparison to the other group, whereas a significant increase in FEV1 and FEF25-75 after salbutamol inhalation was detected 
in patients without antipanic drugs. The subjective anxiety level was not different among PD patients in both test days. 
Discussion: These results suggest a possible beneficial effect of the antipanic drug on lung function in PD patients.
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Resumo
Contexto: Estudos sugerem uma associação entre transtorno de pânico (TP) e prejuízos na função pulmonar. Objetivos: 
Avaliar a função pulmonar em 11 pacientes com TP assintomáticos e investigar efeitos da medicação antipânico na função 
respiratória. Método: A função pulmonar foi avaliada em duas ocasiões diferentes (com medicação antipânico e após 
“washout”). Consistiu de uma avaliação espirométrica e do teste de broncodilatação (inalação de salbutamol). Subjective 
Units of Disturbance Scale (SUDS) foi aplicada antes e após cada teste espirométrico. Resultados: Um paciente apresentou 
obstrução leve de vias aéreas. Antes do teste de broncodilatação, o volume expiratório forçado no primeiro segundo (VEF1) 
e o fluxo expiratório forçado entre 25% e 75% da capacidade vital forçada (FEF25-75) foram significativamente maiores em 
pacientes com medicação antipânico do que no período de “washout”. Após a inalação de salbutamol, apenas o VEF1 foi 
significativamente maior em pacientes com medicação antipânico em comparação ao outro grupo, embora tenha sido de-
tectado aumento significativo em VEF1 e FEF25-75 em pacientes sem medicação antipânico depois da inalação de salbutamol. 
O nível de ansiedade subjetiva não foi diferente entre os pacientes em ambos os dias de testes. Conclusão: Os resultados 
sugerem uma possível ação benéfica da medicação antipânico na função pulmonar em pacientes com TP.
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Introduction
The suffocation false alarm1 and dyspnea-fear theories 
of panic disorder (PD)2 emphasize the central role of 
dyspnea/suffocation symptom in panic attacks. Recently 
several studies have tested these hypotheses relating 
PD with respiratory system3-6. The cingulate gyrus 
and limbic cortex are suprabulbar structures involved 
in the respiratory regulation7. The anterior cingulate 
gyrus produce an inhibitory effect on respiration, and 
serotonin may act as a synaptic transmitter in respiratory 
neurons, may change their sensitivity to external regula-
tory influences, and affect the respiratory response to 
limbic cortex stimulation7.
A growing number of clinical8,9 and epidemiological10 
studies suggests an association of anxiety disorder and 
asthma, although the specificity of this relationship 
remains unclear.
In order to explain the higher lifetime prevalence of 
PD in patients with respiratory disease, some studies 
investigated possible differences in lung function or in 
cognition between asthmatic patients with or without 
PD11-13. Van Peski-Oosterbaan et al.14 observed that 
baseline levels of forced expiratory volume in 1 sec 
(FEV1) and bronchial responsiveness to histamine were 
not significantly different in asthmatic patients with or 
without PD. They suggested that the presence of an 
airway disease or the degree of pulmonary function 
impairment is not related to panic symptoms. Perna 
et al.15 assessed lung function in 17 PD patients with 
or without agoraphobia and 20 healthy controls. They 
showed that PD patients had significantly lower values 
for some dynamic lung parameters, namely, peak expi-
ratory flow rate (PEFR or FEFmax), forced expiratory 
flow at 75% of vital capacity (FEF75) and maximal mid-
expiratory flow rate (MMEF or FEF25-75), suggesting 
subclinical impairment of lung airways. These findings, 
however, could not be replicated16. Carr et al.17 asses-
sed airway impedance in response to a psychological 
stressor among 113 subjects divided in 4 groups: 61 
with asthma alone, 10 with asthma and PD, 24 with PD 
alone, and 18 healthy controls. They demonstrated that 
PD patients (with or without asthma) present lower 
airway impedance (more dilated airways) than those 
without PD, suggesting a respiratory system more 
prepared to react to stress.
Since clinical data suggest that the susceptibility 
to spontaneous as well as CO2-induced anxiety and 
hyperventilation is attenuated by selective serotonin 
reuptake inhibitor (SSRI) antidepressants, Olsson et 
al.18 explored the possible effect of paroxetine (SSRI) 
on baseline respiration and CO2-induced hyperventila-
tion in rats. They suggested that serotonin may influ-
ence brainstem regulation of baseline respiratory rate 
and ventilatory response to hypercapnia. Notably in 
their study tidal volume was not influenced by parox-
etine treatment. Another animal study19 suggested that 
serotonin can induce the contraction of intrapulmonary 
arteriole smooth muscle cells via 5-HT2 receptors. 
Yeragani et al.20 studied the influence of paroxetine 
on respiratory rate and tidal volume among humans 
with PD. They found that paroxetine decreases some 
linear measures of variability of lung volume after 
treatment20. 
The present work was designed to evaluate lung 
function in asymptomatic PD patients with or without 
agoraphobia, who had developed no panic attacks or 
agoraphobic symptoms in the last three months prior 
to the study. The aims were: 1) to investigate possible 
differences in lung function and in the subjective anxi-
ety level on two occasions, with and without antipanic 
drugs; 2) to evaluate the influence of antipanic drugs 
on bronchial responsiveness to salbutamol inhalation in 
PD patients. We hypothesized that PD patients do not 
present any impairment in their lung function.
Methods
We consecutively enrolled 12 PD patients with or wi-
thout agoraphobia who were under treatment at the 
Laboratory of Panic and Respiration of the Federal 
University of Rio de Janeiro, ranging from 18 and 65 
years old, and agreed to participate in this protocol. 
The diagnosis was confirmed by the Structured Clini-
cal Interview21 for DSM-IV22. Patients were clinically 
in good physical condition and were asymptomatic, 
i.e., did not report any panic attacks and agoraphobic 
symptoms in the last three consecutive months before 
the first lung function test. We considered three months 
a safe period to consider the patient remitted from his 
symptoms and consequently in a minimal level of risk 
for recurrency of the panic symptoms during disconti-
nuation and washout periods of antipanic medication. 
Exclusion criteria were the existence of any other 
current mental disorder other than PD, a history of 
psychosis or bipolar disorder, epilepsy, substance abu-
se within the last 6 months, past or current diagnoses 
of respiratory disorders, significant concurrent medical 
problems, personal history of smoking, and pregnant 
or nursing women. The study design was explained 
to the patients and they signed a voluntary written 
informed consent for their participation in this study. 
They were informed that the objective was to assess the 
possible relationship between panic and lung function. 
The protocol, which complied with the principles laid 
down in the Declaration of Helsinki, was approved by 
our Hospital Ethics Committee.
Lung function was assessed on two different days and 
comprised of spirometric evaluation and bronchodilation 
test (salbutamol inhalation). On the first test day all the 
patients were taking their regular antipanic drugs (anti-
depressant and/or benzodiazepine). It is worthy to note 
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that this clinical sample followed the treatment protocol 
of the Laboratory of Panic and Respiration of the Federal 
University of Rio de Janeiro on that time, what indicated 
imipramine as the first choice antidepressant and clona-
zepam as the second medicine of choice to treat panic 
disorder patients. These drugs were reduced gradually 
to avoid discontinuation symptoms and recurrence of 
panic attacks. The patients were asked to washout the 
drugs for at least seven days before the second test day. 
The protocol was carried out in a single-blind fashion, 
so the experimenters performing the lung function test 
did not know whether the patients were taking antipanic 
drugs or not.
Procedure and Data Analysis
Lung function was assessed by spirometry (flow-volume 
and volume-time curves), according to recommenda-
tions of the American Thoracic Society23, at the Labora-
tory of Lung Function, Clementino Fraga Filho Univer-
sity Hospital. All patients were tested in the morning, 
in the sitting position, by a pulmonary physician and a 
nurse trained to perform the test (Pulmonary Function 
System – Modular GS and DSIIA, Warren E. Collins Inc., 
Braintree, MA, USA). Patients were asked to perform 
three forced vital capacity maneuvers, and the highest 
values were used in the analysis. A maximum of eight 
attempts was allowed to obtain three acceptable curves, 
according to acceptability and reproducibility criteria23. 
The following parameters were measured: forced vital 
capacity (FVC); forced expiratory volume in 1 sec 
(FEV1); the ratio between FEV1 and FVC (FEV1/FVC); 
forced expiratory flow between the 25% and 75% of forced 
vital capacity (FEF25-75); the highest instantaneous flow 
during the maneuver (FEFmax); and forced expiratory 
flow at 25% (FEF25), 50% (FEF50) and 75% (FEF75) of 
forced vital capacity. All variables (except FEV1/FVC) 
were expressed as absolute values as well as percenta-
ges of the predicted value according to Knudson et al.24 
After the first session of tests, patients inhaled 400 µg 
of a beta 2-agonist bronchodilator (salbutamol) divided 
in four doses every five minutes. After fifteen minutes, 
the second spirometric evaluation was performed. 
Patients were informed that they might experience 
some discomfort like headache, dizziness, trembling, 
palpitation or symptoms of anxiety with bronchodilator 
administration.
Subjective Units of Disturbance Scale (SUDS)25, 
which reflects the degree of global subjective anxiety 
(ranging from 0 = none to 10 = extreme anxiety) was ap-
plied immediately before the first spirometric evaluation 
(SUDS 1), immediately after it (SUDS 2), immediately 
before the second spirometric evaluation (after inhaled 
bronchodilator) (SUDS 3) and at the end of the experi-
ment (SUDS 4).
To compare the results, firstly, the normality of 
the data (Kolmogorov-Smirnov test with Lilliefors’ 
correction) and the homogeneity of variances (Levene 
median test) were tested. If both conditions were sa-
tisfied, one-way repeated measures ANOVA was used; 
in the negative case, Friedman repeated measures 
ANOVA on ranks was selected instead. If multiple 
comparisons were then required, Student-Newman-
Keuls’ (parametric) or Dunn’s (nonparametric) test 
was applied. The significance level was always set 
at 5%.
Results
One patient did not participate in the second test day 
(“without antipanic drugs” day) and was excluded. The 
remaining patients were 6 men (54.5%) and 5 women 
(45.5%). Their ages ranged from 26 to 47, with a mean 
(± SD) age of 35.6 (± 7.2) years. Ten patients (90.9%) 
also suffered from agoraphobia. 
Tables 1 and 2 show the clinical variables in 11 
PD patients before the first and the second test days, 
respectively. 
Two patients reported limited symptoms of panic 
during washout (cases 6 and 8). 
Only one patient (case 2) reported symptoms just af-
ter salbutamol inhalation on the second test day (without 
antipanic drugs). These symptoms were: dizziness, 
sweating, trembling and palpitation, but the subject did 
not report anxiety or panic symptoms. 
One patient (case 4) presented a mild obstructive 
airway disturbance on both test days that was rever-
sible with bronchodilator administration on second 
test day. 
The SUDS level was not significantly dif ferent 
between the two test days, before and after inhaled 
bronchodilator (Figure 1).
Table 3 shows the mean values (± SD) of all lung 
function parameters.
Considering % predicted value, before bronchodila-
tion test FEV1 and FEF25-75 were significantly higher in 
patients on antipanic drugs than in those in the washout 
period (Table 3). After salbutamol inhalation, only FEV1 
was significantly higher in patients on antipanic drugs 
than in those in the washout period (Table 3). We also 
observed a significant increase in FEV1 and FEF25-75 
after salbutamol inhalation in patients without antipanic 
drugs (Table 3).
Considering absolute values, before bronchodilation 
test FEV1 and FEF25-75 were significantly higher in pa-
tients on antipanic drugs than in those in the washout 
period (Table 3). We observed a significant increase in 
FEV1 and FEF25-75 after salbutamol inhalation in patients 
without antipanic drugs (Table 3).
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Table 1. Clinical variables in 11 panic disorder patients before the first test day








1 16 75 mg/day of imipr plus2 mg/day of clonaz 5 7 7 7
2 10 75 mg/day of imipr plus1 mg/day of clonaz 2 2 3 0
3 11 20 mg/day of parox plus0.25 mg/day of clonaz 6 1 2 1
4 5 1 mg/day of clonaz 1 0 0 0
5 14 50 mg/day of imipr plus1 mg/day of clonaz 10 6 5 3
6 84 75 mg/day of imipr plus10 mg/day of diaz 10 5 2 0
7 24 25 mg/day of imipr 2 2 3 0
8 6 75 mg/day of imipr plus2 mg/day of clonaz 4 0 2 0
9 35 0.5 mg/day of clonaz 2 2 4 3
10 7 25 mg/day of imipr plus1 mg/day of clonaz 0 1 0 0
11 21 75 mg/day of imipr plus0.8 mg/day of clonaz 3 2 2 3
2 Latency: the interval between the first (on medication) and the second (without antipanic drugs) test days (mean 4.3 ± 3.5 months).
 3 Washout period (median: 8.0 days; 25th percentile = 7.0, 75th percentile = 9.5). 
SUDS: Subjective Units of Disturbance Scale. 1: immediately before first spirometric evaluation; 2: immediately after spirometry; 3: immediately before the 
second spirometric evaluation (after salbutamol inhalation); 4: at the end.













1 5.5 8 dizziness, insomnia 4 4 4 4
2 12 7 dizziness, shortness of breath 7 2 2 2
3 4.5 7 dizziness, nausea, “heavy-head” 2 1 1 0
4 2 15 none 3 3 3 3
5 3.5 8 dizziness, trembling, hot wave 2 2 2 8
6 2 7 chest pain, shortness of breath, arterial hypertension, crying 10 5 5 4
7 1 15 none 0 0 0 0
8 4.5 7 none 6 4 2 2
9 2 10 none 2 2 2 2
10 1.5 8 trembling, sweating 0 0 0 0
11 9.5 60 none 4 5 5 4
2 Latency: the interval between the first (on medication) and the second (without antipanic drugs) test days (mean 4.3 ± 3.5 months).
 3 Washout period (median: 8.0 days; 25th percentile = 7.0, 75th percentile = 9.5). 
SUDS: Subjective Units of Disturbance Scale. 1: immediately before first spirometric evaluation; 2: immediately after spirometry; 3: immediately before the 
second spirometric evaluation (after salbutamol inhalation); 4: at the end.
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SUDS: Subjective Units of Disturbance Scale. 1: immediately before first spirometric evaluation; 
2: immediately after spirometry; 3: immediately before the second spirometric evaluation (after 
salbutamol inhalation); 4: at the end. The boundary of the box closest to zero indicates the 25th 
percentile, a line within the box marks the median, and the boundary of the box farthest from zero 
indicates the 75th percentile. Whiskers above and below the box indicate the 90th and 10th percentiles. 
Points represent outliers.
Figure 1. Subjective anxiety level in 11 panic disorder patients in four 
different moments during the lung function assessment with and without 
antipanic drug consumption. 
Table 3. Lung function parameters
Panic disorder patients on antipanic drug
Before salbutamol After salbutamol
Observed % Predicted Observed % Predicted
FVC (L) 4.31 ± 0.95 104.63 ± 12.66 4.31 ± 0.94 104.72 ± 12.24
FEV1(L) 3.58 ± 0.71 107.09 ± 13.74 3.66 ± 0.75 109.27 ± 13.54
FEV1/FVC (%) 83.81 ± 7.69 102.81 ± 8.94 85.36 ± 6.10 104.81 ± 7.32
FEF25-75 (L/sec) 4.00 ± 1.06 110.18 ± 27,84 4.33 ± 1.11 118.72 ± 29.19
FEFmax (L/sec) 9.11 ± 2.57 117.54 ± 22.65 9.23 ± 2.15 119.90 ± 19.89
FEF25 (L/sec) 7.48 ± 1.81 106.81 ± 24.75 7.36 ± 1.92 105.36 ± 25.97
FEF50 (L/sec) 4.80 ± 1.30 106.18 ± 30.69 4.96 ± 1.64 108.81 ± 35.11
FEF75 (L/sec) 1.80 ± 0.57 88.36 ± 33.29 1.99 ± 0.74 96.63 ± 42.26
Panic disorder patients without antipanic drug
Before salbutamol After salbutamol
Observed % Predicted Observed % Predicted
FVC (L) 4.15 ± 0.85 102.90 ± 11.64 4.16 ± 0.92 102.90 ± 12.42
FEV1 (L) 3.42 ± 0.67* 101.81 ± 14.40* 3.54 ± 0.70
# 105.18±13.25* #
FEV1/FVC (%) 82.81 ± 4.66 98.72 ± 5.48 85.72 ± 4.24 102.27 ± 4.56
FEF25-75 (L/sec) 3.67 ± 0.84* 100.45 ± 25.70* 4.11 ± 0.83
# 112.09 ± 24.44#
FEFmax (L/sec) 8.30 ± 1.85 108.18 ± 15.97 8.84 ± 2.48 114.09 ± 20.39
FEF25 (L/sec) 6.98 ± 1.75 98.18 ± 21.98 7.33 ± 1.77 102.81 ± 21.55
FEF50 (L/sec) 4.52 ± 1.16 104.36 ± 29.51 4.89 ± 1.16 112.81 ± 31.73
FEF75 (L/sec) 1.70 ± 0.36 91.36 ± 19.85 1.90 ± 0.43 101.63 ± 22.10
Values are means ± SD of 11 panic disorder patients with and without antipanic drug consumption, before and after salbutamol inhalation. FVC, forced 
vital capacity; FEV1, forced expiratory volume in 1 sec; FEV1/FVC, ratio between FEV1 and FVC; FEF25-75, forced expiratory flow between the 25% and 75% 
of forced vital capacity; FEFmax, the highest instantaneous flow during the maneuver; forced expiratory flow at 25% (FEF25), 50% (FEF50) and 75% (FEF75) of 
forced vital capacity. # Significantly different from value before salbutamol (p < 0.05). * Significantly different from value with antipanic drug (p < 0.05).
Discussion 
Our results suggest that lung function in PD patients 
is normal, as mentioned by Verburg et al.16 Only one 
patient presented a mild reversible airway obstruction 
in response to inhalation of 400 µg of salbutamol. This 
finding could result from either sampling error or 
asymptomatic asthma26. 
We observed higher values of FEV1 and FEF25-75 in 
patients on antipanic drugs than when they were in the 
washout period. This finding persisted in FEV1 even after 
the inhalation of bronchodilator. Salbutamol acted to a 
larger extent in PD patients without antipanic drugs. They 
presented a significant increase in FEV1 and FEF25-75.
Olsson et al.18 found, in rats, a significant increase 
in baseline respiratory rate after 5 and 15 weeks of 
treatment with paroxetine. After 15 weeks of treatment 
the rats presented a reduction in the respiratory rate in 
response to CO2 exposure and suggested that the regu-
lation of respiration may be an important factor for the 













With out antipanic drug
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the change in response of CO2-induced hyperventilation 
to an anxiety-reducing effect of paroxetine because they 
considered that the concentrations of CO2 could not 
provoke anxiety in rats.
Some preliminary studies found sertraline (SSRI) 
useful in the management of dyspnea in chronic obstruc-
tive pulmonary disease and comorbid anxiety and mood 
disorders27,28. It has been reported that the levels of free 
serotonin in plasma are increased in symptomatic patients 
with asthma29,30. Lechin et al.29 randomly assigned 69 chil-
dren with asthma to receive tianeptine, an antidepressant 
drug, and/or placebo in a double-blind crossover trial that 
lasted 52 weeks. Tianeptine caused a sudden decrease in 
both clinical rating and free serotonin plasma levels and 
an improvement in pulmonary function. Nardi and Perna 
also discuss the serotonergic role of clonazepam31.
Perna et al.15 speculated that small airway subclinical 
obstruction in their study might be related to abnor-
malities in the mechanisms controlling bronchial tone, 
principally the tone of the smooth muscles in the small 
airways, finely regulated by autonomic nervous system 
(there are cholinergic, adrenergic and noncholinergic 
nonadrenergic influences). On the other hand, Carr et 
al.17 found that PD patients had wider airways in both 
stressful and non-stressful conditions. 
Although vital capacity maneuvers might increase 
the anxiety level in PD patients owing to hyperventila-
tion and catastrophic misinterpretation of respiratory 
symptoms32, mainly after inhalation of salbutamol, we 
observed that the median of SUDS ranged from 1 to 3 
(Figure 1) without a significant difference. PD patients 
showed similar subjective anxiety levels with and wi-
thout antipanic drugs. Perhaps the control of panic and 
agoraphobic symptoms is responsible for the low anxiety 
index in this sample. 
To our knowledge the present study differs from 
other studies because it includes pulmonary asymp-
tomatic PD patients, whose function tests were deter-
mined with and without antipanic drugs. Some studies 
found an association between panic attacks and anxiety 
sensitivity11,13 that reflects an individual’s concern about 
the consequences of experiencing anxiety-related 
symptoms. Carr et al.13 demonstrated that PD patients, 
asthmatic and nonasthmatic, displayed greater fear of 
bodily sensations on the Body Sensations Questionnai-
re33 and more negative beliefs about the consequences 
of anxiety on the Anxiety Sensitivity Index34 relative to 
those without PD. In addition, the presence of asthma 
alone had no effect on these measures of panic-related 
cognitions, since only asthmatic with PD had elevated 
scores. Finally, scores among asthmatics with PD tended 
to be lower than those among nonasthmatics with PD. 
Carr et al.13 found that anxiety sensitivity was unrelated 
to any of the pulmonary parameters measured (FCV, 
FEV1, FEV1/FCV or FEF50), thus indicating that the 
relationship between anxiety sensitivity and PD was not 
mediated by extra impairment in lung function. Romano 
et al.35 observed a significant reduction in anxiety sensi-
tivity after 6 weeks of treatment with citalopram (SSRI), 
suggesting that fear of the consequences of body sensa-
tion could be normalized by pharmacological treatment 
and that a serotonergic mechanism might be involved 
in changing a cognitive distortion present in PD. These 
authors suggest that the decrease in anxiety sensitivity 
after drug treatment alone challenges the idea that the 
decrease of anxiety sensitivity is selectively mediated 
by cognitive/behavioral treatment36.
The limitations of the study were: 1) the small sample. 
Our results should be interpreted cautiously, because the 
power of the performed test is bellow the desired one. The 
small sample also determined the non-stratification of the 
patients in groups according to their prescription scheme, 
for example one group with persons medicated only with 
SSRI and another one only on tricyclic antidepressants; 2) 
the PD patients were not submitted to a complete medical 
evaluation; 3) it was not possible to discriminate which 
drugs act in lung function (antidepressant, benzodiaze-
pine or both) because of our small sample.
Further studies are required to evaluate if the 
improvement in lung function in asymptomatic PD 
patients is due to the antipanic effects in controlling 
bronchial tone or by decreasing anxiety sensitivity and 
panic-related cognitions. Follow-up studies with samples 
of asthmatic PD patients may also show the impact of 
PD treatment in the respiratory symptoms of asthma. 
Further prospective double-blind studies to evaluate 
pulmonary function on PD patients are required, since 
the acute phase until a remission stage, and stratified 
according to the medication under use (SSRI alone, 
tricyclic antidepressant alone, or these associated with 
benzodiazepines).
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